Reneo Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview

Onkure Therapeutics

05/05/2023 13:20

* Reneo Pharmaceuticals Inc  RPHM.OQ   RPHM.O  is expected
to show
no change in quarterly revenue when it reports  results on May 8
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Reneo
Pharmaceuticals Inc
is for a loss of 60 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 2.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Reneo
Pharmaceuticals Inc is $26.5​, above​ its last closing price
of $9.73. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.60      -0.56     Beat    6.8
 Sep. 30 2022  -0.57       -0.57      -0.53     Beat    7.3
 Jun. 30 2022  -0.58       -0.58      -0.50     Beat    14.1​
 Mar. 31 2022  -0.52       -0.54      -0.53     Beat    2.5
 ​​Dec.        -0.56       -0.57      -0.43     Beat    24.6
 31 2021                                                
 Sep. 30 2021  -0.48       -0.47      -0.52     Missed  -9.9​
 Jun. 30 2021  -0.38       -0.38      -0.43     Missed  -14.2
 Mar. 31 2021  -0.38       -0.38      -3.48     Missed  -815.8
 This summary was machine generated May 5 at 12:20 GMT.  All
figures in US dollars  unless otherwise stated